Global Oncology Market Forecast 2023
Global oncology market is expected to grow in near future as aging and growing population, rising income levels, and emerging medical conditions and emergence of new diseases help increase the demand for oncology treatment.
As per NAVADHI Market Research, global oncology pharmaceutical market will we worth USD 202.54 billion by 2023. The growth in this market is predicted on the basis of various factors like market drivers, current and upcoming trends, current growth pattern, and market challenges.
Oncology had the largest revenue share in Global pharmaceuticals market in FY 2018, and it is expected to retain in it’s leadership position even in 2023.
This growth in oncology market is fueled by the growing and ageing population in key markets. As per World Population Prospects by United Nations, the worldwide population is likely to cross 9.3 billion by 2050 and around 21% of this population is expected to be aged 60 and above. Apart from ageing and rising population the improvements in purchasing power and access to quality healthcare and pharmaceuticals to poor and middle-class families worldwide also is driving the growth of global oncology industry. Another aspect which is leading this growth is rising focus of pharmaceuticals companies to tap the rare and specialty diseases market. Innovations in advanced biologics, nucleic acid therapeutics, cell therapies and bioelectronics & implantables has attracted investments in the industry which is fueling this growth.
On the other hand, adoption of cost control policies along with tightening of rules by governments in key markets are expected to impact the growth prospect of the global oncology industry. Oncology companies are forced to reduce their research and development (R&D) spending due to slowdown of growth in last few years which is also expected to hamper growth of the global oncology market as new drugs revenue form large part of pharma firm’s revenue due to exclusivity of the drug. Apart from this, generics pharma market is facing decreasing return on investment due to price erosion in key markets which is forcing many firms to look for other avenues and markets to sustain growth.
On 3rd January 2019, Bristol-Myers Squibb Company which was ranked 4th based on their FY 2018 oncology revenue announced their plan to acquire Celgene Corporation which was ranked 2nd in the world. The acquisition is expected to cost around USD 90 billion to Bristol-Myers Squibb Company. Post-acquisition Bristol-Myers Squibb Company is expected to give tough competition to Roche Holding AG which is currently world’s top oncology company by FY 2018 revenue.
Spanning over 283 pages and 201 exhibits, “Global Oncology Market Forecast 2023” report provides in-depth analysis for the global oncology pharmaceuticals market for the year FY2018 to FY2023, including market structure, market trends, market constraints and industry drivers.
This report includes detailed company profiles including their position in Global pharmaceuticals market value chain, financial performance analysis, product wise business strategy, competitive landscape and SWOT analysis for 10 key players in Global oncology market namely: Roche Holding AG, Novartis AG, Bristol-Myers Squibb Company, Johnson & Johnson, Merck & Co. Inc., Pfizer Inc, AstraZeneca PLC, Eli Lilly, AbbVie Inc and Astellas Pharma Inc.
Scope of the Global Oncology Market Forecast 2023 Report
As per NAVADHI Market Research, global oncology pharmaceutical market will we worth USD 202.54 billion by 2023. The growth in this market is predicted on the basis of various factors like market drivers, current and upcoming trends, current growth pattern, and market challenges.
Oncology had the largest revenue share in Global pharmaceuticals market in FY 2018, and it is expected to retain in it’s leadership position even in 2023.
This growth in oncology market is fueled by the growing and ageing population in key markets. As per World Population Prospects by United Nations, the worldwide population is likely to cross 9.3 billion by 2050 and around 21% of this population is expected to be aged 60 and above. Apart from ageing and rising population the improvements in purchasing power and access to quality healthcare and pharmaceuticals to poor and middle-class families worldwide also is driving the growth of global oncology industry. Another aspect which is leading this growth is rising focus of pharmaceuticals companies to tap the rare and specialty diseases market. Innovations in advanced biologics, nucleic acid therapeutics, cell therapies and bioelectronics & implantables has attracted investments in the industry which is fueling this growth.
On the other hand, adoption of cost control policies along with tightening of rules by governments in key markets are expected to impact the growth prospect of the global oncology industry. Oncology companies are forced to reduce their research and development (R&D) spending due to slowdown of growth in last few years which is also expected to hamper growth of the global oncology market as new drugs revenue form large part of pharma firm’s revenue due to exclusivity of the drug. Apart from this, generics pharma market is facing decreasing return on investment due to price erosion in key markets which is forcing many firms to look for other avenues and markets to sustain growth.
On 3rd January 2019, Bristol-Myers Squibb Company which was ranked 4th based on their FY 2018 oncology revenue announced their plan to acquire Celgene Corporation which was ranked 2nd in the world. The acquisition is expected to cost around USD 90 billion to Bristol-Myers Squibb Company. Post-acquisition Bristol-Myers Squibb Company is expected to give tough competition to Roche Holding AG which is currently world’s top oncology company by FY 2018 revenue.
Spanning over 283 pages and 201 exhibits, “Global Oncology Market Forecast 2023” report provides in-depth analysis for the global oncology pharmaceuticals market for the year FY2018 to FY2023, including market structure, market trends, market constraints and industry drivers.
This report includes detailed company profiles including their position in Global pharmaceuticals market value chain, financial performance analysis, product wise business strategy, competitive landscape and SWOT analysis for 10 key players in Global oncology market namely: Roche Holding AG, Novartis AG, Bristol-Myers Squibb Company, Johnson & Johnson, Merck & Co. Inc., Pfizer Inc, AstraZeneca PLC, Eli Lilly, AbbVie Inc and Astellas Pharma Inc.
Scope of the Global Oncology Market Forecast 2023 Report
- This report provides detailed information about Global oncology market including future market forecasts till 2023.
- This report identifies the need for focusing on global oncology market.
- The report identifies the growth drivers and inhibitors for global oncology market.
- The report identifies various risks associated with global oncology market.
- This report has detailed profiles top 10 key players in Global oncology market covering their business strategy, financial performance, future forecasts and SWOT analysis.
- This report provides competitive landscape among top 10 key companies in Global oncology market.
- This report provides Porter’s Five Forces analysis for Global oncology market.
- This report provides SWOT (strengths, weakness, opportunities and threats) analysis for Global oncology market.
- This report provides information about current and future trends for Global oncology market.
1. EXECUTIVE SUMMARY
Scope of the Global Oncology Market Forecast 2023 Report
Research Methodology
2. INTRODUCTION OF PHARMACEUTICALS INDUSTRY
Key Product Terms Used in Pharmaceuticals Industry
Pharmaceuticals
Innovative Drugs
Orphan Drugs
Generic Drugs
Commodity Generic Drugs
Branded Generic Drugs
Biologics
Biosimilars
Over-the-counter (OTC) Drugs
Active Pharmaceutical Ingredients (APIs)
Excipients
Research and Development (R&D) Phases of Pharmaceuticals Industry
Industry-Wise Research and Development (R&D) Investment
Phase Wise Research and Development (R&D) Investment in Pharmaceuticals Industry
Global Pharmaceuticals Industry Value Chain Analysis
3. NEED FOR GLOBAL ONCOLOGY MARKET
Rising & Ageing Global Population
Increasing Income Levels of Poor & Middle-Class Families
4. FORECAST FOR GLOBAL ONCOLOGY MARKET 2023
4.1 Therapy Area-Wise Forecast for Global Pharmaceuticals Market 2018-2023
4.1.1 Forecast for Global Oncology Pharmaceuticals Market 2018-2023
5. GROWTH DRIVERS AND INHIBITORS FOR GLOBAL ONCOLOGY MARKET
6. RISKS ASSOCIATED WITH GLOBAL ONCOLOGY MARKET
6.1 Risk of Patent Expiry and Loss of Intellectual Property Protection
6.2 Risk of Commercial Success of New Products
6.3 Risk of Failed Research and Development Effort
6.4 Risk of Drug Price Controls
6.5 Risk of Failure to Comply with New Laws and Regulations
6.6 Risk of Quality Control During Complex Manufacturing Process
6.7 Risk of Cyber-Attacks and Data Breach
6.8 Risk of Volatile Currency Exchange Rates and Interest Rates
6.9 Risk of Unstable Global Political and Economic Conditions
7. INDUSTRY ASSOCIATIONS RELATED TO GLOBAL PHARMACEUTICALS MARKET
7.1 European Federation of Pharmaceutical Industries and Associations (EFPIA)
7.2 International Federation of Pharmaceutical Manufacturers & Associations (IFPMA)
7.3 Pharmaceutical Research and Manufacturers of America (PhRMA)
7.4 Association of the British Pharmaceutical Industry (ABPI)
7.5 Japan Pharmaceutical Manufacturers Association (JPMA)
7.6 Indian Drug Manufacturers' Association (IDMA)
8. PROFILE OF KEY PLAYERS IN GLOBAL ONCOLOGY MARKET
8.1 Pfizer Inc.
8.1.1 Company Profile
8.1.2 Pfizer Inc. in Global Pharmaceuticals Manufacturing Value Chain
8.1.3 Pfizer Inc.: Financial Performance
8.1.3.1 Pfizer Inc.: Overall Revenue FY 2013-FY 2019 (in USD billion)
8.1.3.2 Pfizer Inc.: Geography-Wise Revenue FY 2018 (in USD billion)
8.1.3.3 Pfizer Inc.: Therapy Area-Wise Revenue FY 2018 (in USD billion)
8.1.4 Pfizer Inc.: Business Strategy
8.1.4.1 Product Level Strategy
8.1.5 SWOT Analysis of Pfizer Inc.
Strengths
Weaknesses
Opportunities
Threats
8.2 Novartis AG
8.2.1 Company Profile
8.2.2 Novartis AG in Global Pharmaceuticals Manufacturing Value Chain
8.2.3 Novartis AG: Financial Performance
8.2.3.1 Novartis AG: Overall Revenue FY 2013-FY 2019 (in USD billion)
8.2.3.2 Novartis AG: Geography-Wise Revenue FY 2018 (in USD billion)
8.2.3.3 Novartis AG: Therapy Area-Wise Revenue FY 2018 (in USD billion)
8.2.4 Novartis AG: Business Strategy
8.2.5 SWOT Analysis of Novartis AG
Strengths
Weaknesses
Opportunities
Threats
8.3 Johnson & Johnson
8.3.1 Company Profile
8.3.2 Johnson & Johnson in Global Pharmaceuticals Manufacturing Value Chain
8.3.3 Johnson & Johnson Financial Performance
8.3.3.1 Johnson & Johnson: Overall Revenue FY 2013-FY 2019 (in USD billion)
8.3.3.2 Johnson & Johnson: Division-Wise Revenue FY 2018 (in USD billion)
8.3.3.3 Johnson & Johnson: Geography-Wise Revenue FY 2018 (in USD billion)
8.3.3.4 Johnson & Johnson: Therapy Area-Wise Revenue FY 2018 (in USD billion)
8.3.4 Johnson & Johnson: Business Strategy
8.3.4.1 Product Level Business Strategy
8.3.5 Johnson & Johnson’s Pharmaceutical Division Growth Drivers
8.3.6 SWOT Analysis of Johnson & Johnson
Strengths
Weaknesses
Opportunities
Threats
8.4 AstraZeneca PLC
8.4.1 Company Profile
8.4.2 AstraZeneca PLC in Global Pharmaceuticals Manufacturing Value Chain
8.4.3 AstraZeneca PLC: Financial Performance
8.4.3.1 AstraZeneca PLC: Overall Revenue FY 2013-FY 2019 (in USD billion)
8.4.3.2 AstraZeneca PLC: Geography-Wise Revenue FY 2018 (in USD billion)
8.4.3.3 AstraZeneca PLC: Therapy Area-Wise Revenue FY 2018 (in USD billion)
8.4.4 AstraZeneca PLC: Business Strategy
8.4.4.1 Product Level Strategy
8.4.5 SWOT Analysis of AstraZeneca PLC
Strengths
Weaknesses
Opportunities
Threats
8.5 Roche Holding AG
8.5.1 Company Profile
8.5.2 Roche Holding AG in Global Pharmaceuticals Manufacturing Value Chain
8.5.3 Roche Holding AG: Financial Performance
8.5.3.1 Roche Holding AG: Overall Revenue FY 2013-FY 2019 (in CHF billion)
8.5.3.2 Roche Holding AG: Geography-Wise Revenue FY 2018 (in CHF billion)
8.5.3.3 Roche Holding AG: Division-Wise Revenue FY 2018 (in CHF billion)
8.5.3.4 Roche Holding AG: Therapy Area-Wise Pharmaceuticals Revenue FY 2018 (in CHF billion)
8.5.3.5 Roche Holding AG: Segment-Wise Diagnostics Revenue FY 2018 (in CHF billion)
8.5.4 Roche Holding AG: Business Strategy
8.5.4.1 Product Level Strategy
8.5.5 SWOT Analysis of Roche Holding AG
Strengths
Weaknesses
Opportunities
Threats
8.5.6 Key Customers of Roche Holding AG
8.6 Merck & Co., Inc.
8.6.1 Company Profile
8.6.2 Merck & Co., Inc. in Global Pharmaceuticals Manufacturing Value Chain
8.6.3 Merck & Co., Inc.: Financial Performance
8.6.3.1 Merck & Co., Inc.: Overall Revenue FY 2013-FY 2019 (in USD billion)
8.6.3.2 Merck & Co., Inc.: Division-Wise Revenue FY 2018 (in USD billion)
8.6.3.3 Merck & Co., Inc.: Geography-Wise Revenue FY 2018 (in USD billion)
8.6.3.4 Merck & Co., Inc.: Therapy Area-Wise Revenue FY 2018 (in USD billion)
8.6.4 Merck & Co., Inc.: Business Strategy
8.6.4.1 Product Level Strategy
8.6.5 SWOT Analysis of Merck & Co., Inc.
Strengths
Weaknesses
Opportunities
Threats
8.7 Astellas Pharma Inc
8.7.1 Company Profile
8.7.2 Astellas Pharma Inc. in Pharmaceuticals Manufacturing Value Chain
8.7.3 Astellas Pharma Inc.: Financial Performance
8.7.3.1 Astellas Pharma Inc: Overall Revenue FY 2013-FY 2019 (in USD billion)
8.4.3.2 Astellas Pharma Inc: Geography-Wise Revenue FY 2018 (in USD billion)
8.7.3.3 Astellas Pharma Inc: Therapy Area-Wise Revenue FY 2018 (in USD billion)
8.7.4 Astellas Pharma Inc.: Business Strategy
8.7.4.1 Product Level Strategy
8.7.5 SWOT Analysis of Astellas Pharma Inc.
Strengths
Weaknesses
Opportunities
Threats
8.7.6 Key Customers of Astellas Pharma Inc.
8.8 AbbVie Inc.
8.8.1 Company Profile
8.8.2 AbbVie Inc. in Global Pharmaceuticals Manufacturing Value Chain
8.8.3 AbbVie Inc.: Financial Performance
8.8.3.1 AbbVie Inc.: Overall Revenue FY 2013-FY 2019 (in USD billion)
8.8.3.2 AbbVie Inc.: Geography-Wise Revenue FY 2018 (in USD billion)
8.8.3.3 AbbVie Inc.: Therapy Area-Wise Revenue FY 2018 (in USD billion)
8.8.4 AbbVie Inc.: Business Strategy
8.8.4.1 Product Level Strategy
8.8.5 SWOT Analysis of AbbVie Inc.
Strengths
Weaknesses
Opportunities
Threats
8.9 Eli Lilly and Company
8.9.1 Company Profile
8.9.2 Eli Lilly in Global Pharmaceuticals Manufacturing Value Chain
8.9.3 Eli Lilly: Financial Performance
8.9.3.1 Eli Lilly: Overall Revenue FY 2013-FY 2019 (in USD billion)
8.9.3.2 Eli Lilly: Geography-Wise Revenue FY 2018 (in USD billion)
8.9.3.3 Eli Lilly: Division-Wise Revenue FY 2018 (in USD billion)
8.9.3.4 Eli Lilly: Geography-Wise Pharmaceuticals Revenue FY 2018 (in USD billion)
8.9.3.5 Eli Lilly: Therapy Area-Wise Revenue FY 2018 (in USD billion)
8.9.4 Eli Lilly: Business Strategy
8.9.4.1 Product Level Strategy
8.9.5 SWOT Analysis of Eli Lilly and Company
Strengths
Weaknesses
Opportunities
Threats
8.10 Bristol-Myers Squib Company
8.10.1 Company Profile
8.10.2 Bristol-Myers Squibb Company in Pharmaceuticals Manufacturing Value Chain
8.10.3 Bristol-Myers Squibb Company: Financial Performance
8.10.3.1 Bristol-Myers Squibb Company: Overall Revenue FY 2013-FY 2019 (in USD billion)
8.10.3.2 Bristol-Myers Squibb Company: Geography-Wise Revenue FY 2018 (in USD billion)
8.10.3.3 Bristol-Myers Squibb Company: Brand-Wise Pharmaceuticals Revenue FY 2018 (in USD billion)
8.10.4 Bristol-Myers Squibb Company: Business Strategy
8.10.4.1 Product Level Strategy
8.10.5 SWOT Analysis of Bristol-Myers Squibb Company
Strengths
Weaknesses
Opportunities
Threats
9. COMPETITIVE LANDSCAPE IN GLOBAL ONCOLOGY MARKET
9.1 Competitive Landscape Among Top 10 Oncology Companies by Oncology Revenue
9.2 Competitive Landscape Among Top 10 Oncology Companies by Overall Revenue
9.3 Competitive Landscape Among Top 10 Oncology Companies by Global Pharmaceuticals Revenue
9.4 Competitive Landscape Among Top 10 Oncology Companies by United States Revenue
9.5 Competitive Landscape Among Top 10 Oncology Companies by Research and Development (R&D) Expenditure
9.6 Competitive Landscape Among Top 10 Oncology Companies by Earning Per Share (EPS)
9.7 Competitive Landscape Among Top 10 Oncology Companies by Earnings Before Interest, Tax, Depreciation and Amortization (EBITDA)
9.8 Competitive Landscape Among Top 10 Oncology Companies by Overall Revenue Forecast
9.9 Competitive Landscape Among Top 10 Oncology Companies by Top 3 Product Revenues
10. ANALYSIS OF GLOBAL ONCOLOGY MARKET
10.1 Porter’s Five Forces Analysis of Global Oncology Market
10.2 SWOT Analysis of Global Oncology Market
Strengths
Weaknesses
Opportunities
Threats
11. CURRENT AND FUTURE TRENDS IN GLOBAL ONCOLOGY MARKET
Notes
Company Information
Scope of the Global Oncology Market Forecast 2023 Report
Research Methodology
2. INTRODUCTION OF PHARMACEUTICALS INDUSTRY
Key Product Terms Used in Pharmaceuticals Industry
Pharmaceuticals
Innovative Drugs
Orphan Drugs
Generic Drugs
Commodity Generic Drugs
Branded Generic Drugs
Biologics
Biosimilars
Over-the-counter (OTC) Drugs
Active Pharmaceutical Ingredients (APIs)
Excipients
Research and Development (R&D) Phases of Pharmaceuticals Industry
Industry-Wise Research and Development (R&D) Investment
Phase Wise Research and Development (R&D) Investment in Pharmaceuticals Industry
Global Pharmaceuticals Industry Value Chain Analysis
3. NEED FOR GLOBAL ONCOLOGY MARKET
Rising & Ageing Global Population
Increasing Income Levels of Poor & Middle-Class Families
4. FORECAST FOR GLOBAL ONCOLOGY MARKET 2023
4.1 Therapy Area-Wise Forecast for Global Pharmaceuticals Market 2018-2023
4.1.1 Forecast for Global Oncology Pharmaceuticals Market 2018-2023
5. GROWTH DRIVERS AND INHIBITORS FOR GLOBAL ONCOLOGY MARKET
6. RISKS ASSOCIATED WITH GLOBAL ONCOLOGY MARKET
6.1 Risk of Patent Expiry and Loss of Intellectual Property Protection
6.2 Risk of Commercial Success of New Products
6.3 Risk of Failed Research and Development Effort
6.4 Risk of Drug Price Controls
6.5 Risk of Failure to Comply with New Laws and Regulations
6.6 Risk of Quality Control During Complex Manufacturing Process
6.7 Risk of Cyber-Attacks and Data Breach
6.8 Risk of Volatile Currency Exchange Rates and Interest Rates
6.9 Risk of Unstable Global Political and Economic Conditions
7. INDUSTRY ASSOCIATIONS RELATED TO GLOBAL PHARMACEUTICALS MARKET
7.1 European Federation of Pharmaceutical Industries and Associations (EFPIA)
7.2 International Federation of Pharmaceutical Manufacturers & Associations (IFPMA)
7.3 Pharmaceutical Research and Manufacturers of America (PhRMA)
7.4 Association of the British Pharmaceutical Industry (ABPI)
7.5 Japan Pharmaceutical Manufacturers Association (JPMA)
7.6 Indian Drug Manufacturers' Association (IDMA)
8. PROFILE OF KEY PLAYERS IN GLOBAL ONCOLOGY MARKET
8.1 Pfizer Inc.
8.1.1 Company Profile
8.1.2 Pfizer Inc. in Global Pharmaceuticals Manufacturing Value Chain
8.1.3 Pfizer Inc.: Financial Performance
8.1.3.1 Pfizer Inc.: Overall Revenue FY 2013-FY 2019 (in USD billion)
8.1.3.2 Pfizer Inc.: Geography-Wise Revenue FY 2018 (in USD billion)
8.1.3.3 Pfizer Inc.: Therapy Area-Wise Revenue FY 2018 (in USD billion)
8.1.4 Pfizer Inc.: Business Strategy
8.1.4.1 Product Level Strategy
8.1.5 SWOT Analysis of Pfizer Inc.
Strengths
Weaknesses
Opportunities
Threats
8.2 Novartis AG
8.2.1 Company Profile
8.2.2 Novartis AG in Global Pharmaceuticals Manufacturing Value Chain
8.2.3 Novartis AG: Financial Performance
8.2.3.1 Novartis AG: Overall Revenue FY 2013-FY 2019 (in USD billion)
8.2.3.2 Novartis AG: Geography-Wise Revenue FY 2018 (in USD billion)
8.2.3.3 Novartis AG: Therapy Area-Wise Revenue FY 2018 (in USD billion)
8.2.4 Novartis AG: Business Strategy
8.2.5 SWOT Analysis of Novartis AG
Strengths
Weaknesses
Opportunities
Threats
8.3 Johnson & Johnson
8.3.1 Company Profile
8.3.2 Johnson & Johnson in Global Pharmaceuticals Manufacturing Value Chain
8.3.3 Johnson & Johnson Financial Performance
8.3.3.1 Johnson & Johnson: Overall Revenue FY 2013-FY 2019 (in USD billion)
8.3.3.2 Johnson & Johnson: Division-Wise Revenue FY 2018 (in USD billion)
8.3.3.3 Johnson & Johnson: Geography-Wise Revenue FY 2018 (in USD billion)
8.3.3.4 Johnson & Johnson: Therapy Area-Wise Revenue FY 2018 (in USD billion)
8.3.4 Johnson & Johnson: Business Strategy
8.3.4.1 Product Level Business Strategy
8.3.5 Johnson & Johnson’s Pharmaceutical Division Growth Drivers
8.3.6 SWOT Analysis of Johnson & Johnson
Strengths
Weaknesses
Opportunities
Threats
8.4 AstraZeneca PLC
8.4.1 Company Profile
8.4.2 AstraZeneca PLC in Global Pharmaceuticals Manufacturing Value Chain
8.4.3 AstraZeneca PLC: Financial Performance
8.4.3.1 AstraZeneca PLC: Overall Revenue FY 2013-FY 2019 (in USD billion)
8.4.3.2 AstraZeneca PLC: Geography-Wise Revenue FY 2018 (in USD billion)
8.4.3.3 AstraZeneca PLC: Therapy Area-Wise Revenue FY 2018 (in USD billion)
8.4.4 AstraZeneca PLC: Business Strategy
8.4.4.1 Product Level Strategy
8.4.5 SWOT Analysis of AstraZeneca PLC
Strengths
Weaknesses
Opportunities
Threats
8.5 Roche Holding AG
8.5.1 Company Profile
8.5.2 Roche Holding AG in Global Pharmaceuticals Manufacturing Value Chain
8.5.3 Roche Holding AG: Financial Performance
8.5.3.1 Roche Holding AG: Overall Revenue FY 2013-FY 2019 (in CHF billion)
8.5.3.2 Roche Holding AG: Geography-Wise Revenue FY 2018 (in CHF billion)
8.5.3.3 Roche Holding AG: Division-Wise Revenue FY 2018 (in CHF billion)
8.5.3.4 Roche Holding AG: Therapy Area-Wise Pharmaceuticals Revenue FY 2018 (in CHF billion)
8.5.3.5 Roche Holding AG: Segment-Wise Diagnostics Revenue FY 2018 (in CHF billion)
8.5.4 Roche Holding AG: Business Strategy
8.5.4.1 Product Level Strategy
8.5.5 SWOT Analysis of Roche Holding AG
Strengths
Weaknesses
Opportunities
Threats
8.5.6 Key Customers of Roche Holding AG
8.6 Merck & Co., Inc.
8.6.1 Company Profile
8.6.2 Merck & Co., Inc. in Global Pharmaceuticals Manufacturing Value Chain
8.6.3 Merck & Co., Inc.: Financial Performance
8.6.3.1 Merck & Co., Inc.: Overall Revenue FY 2013-FY 2019 (in USD billion)
8.6.3.2 Merck & Co., Inc.: Division-Wise Revenue FY 2018 (in USD billion)
8.6.3.3 Merck & Co., Inc.: Geography-Wise Revenue FY 2018 (in USD billion)
8.6.3.4 Merck & Co., Inc.: Therapy Area-Wise Revenue FY 2018 (in USD billion)
8.6.4 Merck & Co., Inc.: Business Strategy
8.6.4.1 Product Level Strategy
8.6.5 SWOT Analysis of Merck & Co., Inc.
Strengths
Weaknesses
Opportunities
Threats
8.7 Astellas Pharma Inc
8.7.1 Company Profile
8.7.2 Astellas Pharma Inc. in Pharmaceuticals Manufacturing Value Chain
8.7.3 Astellas Pharma Inc.: Financial Performance
8.7.3.1 Astellas Pharma Inc: Overall Revenue FY 2013-FY 2019 (in USD billion)
8.4.3.2 Astellas Pharma Inc: Geography-Wise Revenue FY 2018 (in USD billion)
8.7.3.3 Astellas Pharma Inc: Therapy Area-Wise Revenue FY 2018 (in USD billion)
8.7.4 Astellas Pharma Inc.: Business Strategy
8.7.4.1 Product Level Strategy
8.7.5 SWOT Analysis of Astellas Pharma Inc.
Strengths
Weaknesses
Opportunities
Threats
8.7.6 Key Customers of Astellas Pharma Inc.
8.8 AbbVie Inc.
8.8.1 Company Profile
8.8.2 AbbVie Inc. in Global Pharmaceuticals Manufacturing Value Chain
8.8.3 AbbVie Inc.: Financial Performance
8.8.3.1 AbbVie Inc.: Overall Revenue FY 2013-FY 2019 (in USD billion)
8.8.3.2 AbbVie Inc.: Geography-Wise Revenue FY 2018 (in USD billion)
8.8.3.3 AbbVie Inc.: Therapy Area-Wise Revenue FY 2018 (in USD billion)
8.8.4 AbbVie Inc.: Business Strategy
8.8.4.1 Product Level Strategy
8.8.5 SWOT Analysis of AbbVie Inc.
Strengths
Weaknesses
Opportunities
Threats
8.9 Eli Lilly and Company
8.9.1 Company Profile
8.9.2 Eli Lilly in Global Pharmaceuticals Manufacturing Value Chain
8.9.3 Eli Lilly: Financial Performance
8.9.3.1 Eli Lilly: Overall Revenue FY 2013-FY 2019 (in USD billion)
8.9.3.2 Eli Lilly: Geography-Wise Revenue FY 2018 (in USD billion)
8.9.3.3 Eli Lilly: Division-Wise Revenue FY 2018 (in USD billion)
8.9.3.4 Eli Lilly: Geography-Wise Pharmaceuticals Revenue FY 2018 (in USD billion)
8.9.3.5 Eli Lilly: Therapy Area-Wise Revenue FY 2018 (in USD billion)
8.9.4 Eli Lilly: Business Strategy
8.9.4.1 Product Level Strategy
8.9.5 SWOT Analysis of Eli Lilly and Company
Strengths
Weaknesses
Opportunities
Threats
8.10 Bristol-Myers Squib Company
8.10.1 Company Profile
8.10.2 Bristol-Myers Squibb Company in Pharmaceuticals Manufacturing Value Chain
8.10.3 Bristol-Myers Squibb Company: Financial Performance
8.10.3.1 Bristol-Myers Squibb Company: Overall Revenue FY 2013-FY 2019 (in USD billion)
8.10.3.2 Bristol-Myers Squibb Company: Geography-Wise Revenue FY 2018 (in USD billion)
8.10.3.3 Bristol-Myers Squibb Company: Brand-Wise Pharmaceuticals Revenue FY 2018 (in USD billion)
8.10.4 Bristol-Myers Squibb Company: Business Strategy
8.10.4.1 Product Level Strategy
8.10.5 SWOT Analysis of Bristol-Myers Squibb Company
Strengths
Weaknesses
Opportunities
Threats
9. COMPETITIVE LANDSCAPE IN GLOBAL ONCOLOGY MARKET
9.1 Competitive Landscape Among Top 10 Oncology Companies by Oncology Revenue
9.2 Competitive Landscape Among Top 10 Oncology Companies by Overall Revenue
9.3 Competitive Landscape Among Top 10 Oncology Companies by Global Pharmaceuticals Revenue
9.4 Competitive Landscape Among Top 10 Oncology Companies by United States Revenue
9.5 Competitive Landscape Among Top 10 Oncology Companies by Research and Development (R&D) Expenditure
9.6 Competitive Landscape Among Top 10 Oncology Companies by Earning Per Share (EPS)
9.7 Competitive Landscape Among Top 10 Oncology Companies by Earnings Before Interest, Tax, Depreciation and Amortization (EBITDA)
9.8 Competitive Landscape Among Top 10 Oncology Companies by Overall Revenue Forecast
9.9 Competitive Landscape Among Top 10 Oncology Companies by Top 3 Product Revenues
10. ANALYSIS OF GLOBAL ONCOLOGY MARKET
10.1 Porter’s Five Forces Analysis of Global Oncology Market
10.2 SWOT Analysis of Global Oncology Market
Strengths
Weaknesses
Opportunities
Threats
11. CURRENT AND FUTURE TRENDS IN GLOBAL ONCOLOGY MARKET
Notes
Company Information
LIST OF EXHIBITS
Exhibit 2.1 Research and Development Phases of Pharmaceuticals Industry
Exhibit 2.2 Industry-Wise Research and Development Investment in Comparison to Net Sales (in %)
Exhibit 2.3 Phase-Wise Research and Development Investment in Pharmaceuticals Industry
Exhibit 2.4 Global Pharmaceuticals Industry Value Chain Analysis
Exhibit 3.1 Country-Wise Population Forecast 2016-2023 (in millions)
Exhibit 3.2 Country-Wise Purchasing Power Parity Based Per Capita GDP Forecast 2016-2023 (in USD)
Exhibit 4.1 Therapy Area-wise Market Share in Global Pharmaceuticals Market in 2017 (in %)
Exhibit 4.2 Forecast for Global Oncology Pharmaceuticals Market 2018-2023 (in USD billion)
Exhibit 5.1 Growth Drivers and Inhibitors for Global Oncology Market
Exhibit 6.1 Country-Wise Drug Price Control Policies in Global Pharmaceuticals Market
Exhibit 7.1 Key Information of EFPIA
Exhibit 7.2 Contact details of EFPIA
Exhibit 7.3 List of EFPIA Members
Exhibit 7.4 Key Information of IFPMA
Exhibit 7.5 Contact details of IFPMA
Exhibit 7.6 List of IFPMA Members
Exhibit 7.7 Key Information of PhRMA
Exhibit 7.8 Contact details of PhRMA
Exhibit 7.9 List of PhRMA Members
Exhibit 7.10 Key information of ABPI
Exhibit 7.11 Contact details of ABPI
Exhibit 7.12 List of ABPI Members
Exhibit 7.13 Key Information of JPMA
Exhibit 7.13 Key Information of JPMA
Exhibit 7.15 List of JPMA Members
Exhibit 7.16 Key information of IDMA
Exhibit 7.17 Contact details of IDMA
Exhibit 8.1 Key Information of Pfizer Inc.
Exhibit 8.2 Contact information of Pfizer Inc.
Exhibit 8.3 Pfizer Inc. in Pharmaceuticals Manufacturing Value Chain
Exhibit 8.4 Revenue of Pfizer Inc. FY 2013- FY 2019 (in USD billion)
Exhibit 8.5 Revenue Growth of Pfizer Inc. FY 2014- FY 2019 (in %)
Exhibit 8.6 Geography-Wise Revenue of Pfizer Inc. in FY 2018 (in USD billion)
Exhibit 8.7 Therapy Area-Wise Revenue of Pfizer Inc. in FY 2018 (in USD billion)
Exhibit 8.8 Therapy and Geography Area-Wise Revenue of Pfizer Inc. FY 2018 (in USD billion)j
Exhibit 8.9 SWOT Analysis of Pfizer Inc.
Exhibit 8.10 Key Information of Novartis AG
Exhibit 8.11 Contact Information of Novartis AG
Exhibit 8.12 Novartis AG in Pharmaceuticals Manufacturing Value Chain
Exhibit 8.13 Revenue of Novartis AG FY 2013- FY 2019 (in USD billion)
Exhibit 8.14 Revenue Growth of Novartis AG FY 2014- FY 2019 (in %)
Exhibit 8.15 Geography-Wise Revenue of Novartis AG in FY 2018 (in USD billion)
Exhibit 8.16 Therapy and Geography Area-Wise Revenue of Pfizer Inc. FY 2018 (in USD million)
Exhibit 8.17 Business Division-Wise Revenue of Novartis AG in FY 2018 (in USD million)
Exhibit 8.18 Innovative Medicines Division Revenue of Novartis AG FY 2017- FY 2019 (in USD billion)
Exhibit 8.19 Sandoz Division Revenue of Novartis AG FY 2017- FY 2019 (in USD billion)
Exhibit 8.20 Alcon Division Revenue of Novartis AG FY 2017- FY 2019 (in USD billion)
Exhibit 8.21 10+ potential blockbuster launches planned by Novartis AG in the next 2 years
Exhibit 8.22 SWOT Analysis of Novartis AG
Exhibit 8.23 Key Information of Johnson & Johnson
Exhibit 8.24 Contact information of Johnson & Johnson
Exhibit 8.25 Johnson & Johnson in Pharmaceuticals Manufacturing Value Chain
Exhibit 8.26 Revenue of Johnson & Johnson FY 2013- FY 2019 (in USD billion)
Exhibit 8.27 Revenue Growth of Johnson & Johnson FY 2014- FY 2019 (in %)
Exhibit 8.28 Division-Wise Revenue of Johnson & Johnson in FY 2018 (in USD billion)
Exhibit 8.29 Consumer Division Revenue of Johnson & Johnson FY 2013- FY 2018 (in USD billion)
Exhibit 8.30 Pharmaceuticals Division Revenue of Johnson & Johnson FY 2013- FY 2018 (in USD billion)
Exhibit 8.31 Medical Devices Division Revenue of Johnson & Johnson FY 2013- FY 2018 (in USD billion)
Exhibit 8.32 Geography-Wise Revenue of Johnson & Johnson in FY 2018 (in USD billion)
Exhibit 8.33 Therapy Area-Wise Revenue of Johnson & Johnson in FY 2018 (in USD billion)
Exhibit 8.34 Therapy and Geography Area-Wise Revenue of Johnson & Johnson FY 2018 (in USD billion)
Exhibit 8.35 SWOT Analysis of Johnson & Johnson
Exhibit 8.36 Key Information of AstraZeneca PLC
Exhibit 8.37 Contact Information of AstraZeneca PLC
Exhibit 8.38 AstraZeneca PLC in Pharmaceuticals Manufacturing Value Chain
Exhibit 8.39 Revenue of AstraZeneca PLC FY 2013-FY 2019 (in USD billion)
Exhibit 8.40 Revenue Growth of AstraZeneca PLC FY 2014-FY 2019 (in %)
Exhibit 8.41 Geography-Wise Revenue of AstraZeneca PLC in FY 2018 (in USD billion)
Exhibit 8.42 United States Revenue of AstraZeneca PLC FY 2014-FY 2018 (in USD billion)
Exhibit 8.43 United States Revenue Growth of AstraZeneca PLC FY 2015-FY 2018 (in %)
Exhibit 8.44 China Revenue of AstraZeneca PLC FY 2014-FY 2018 (in USD billion)
Exhibit 8.45 China Revenue Growth of AstraZeneca PLC FY 2015-FY 2018 (in %)
Exhibit 8.46 United Kingdom Revenue of AstraZeneca PLC FY 2014-FY 2018 (in USD billion)
Exhibit 8.47 United Kingdom Revenue Growth of AstraZeneca PLC FY 2015-FY 2018 (in %)
Exhibit 8.48 France Revenue of AstraZeneca PLC FY 2014-FY 2018 (in USD billion)
Exhibit 8.49 France Revenue Growth of AstraZeneca PLC FY 2015-FY 2018 (in %)
Exhibit 8.50 Germany Revenue of AstraZeneca PLC FY 2014-FY 2018 (in USD billion)
Exhibit 8.51 Germany Revenue Growth of AstraZeneca PLC FY 2015-FY 2018 (in %)
Exhibit 8.52 Italy Revenue of AstraZeneca PLC FY 2014-FY 2018 (in USD billion)
Exhibit 8.53 Italy Revenue Growth of AstraZeneca PLC FY 2015-FY 2018 (in %)
Exhibit 8.54 Spain Revenue of AstraZeneca PLC FY 2014-FY 2018 (in USD billion)
Exhibit 8.55 Spain Revenue Growth of AstraZeneca PLC FY 2015-FY 2018 (in %)
Exhibit 8.56 Sweden Revenue of AstraZeneca PLC FY 2014-FY 2018 (in USD billion)
Exhibit 8.57 Sweden Revenue Growth of AstraZeneca PLC FY 2015-FY 2018 (in %)
Exhibit 8.58 Rest of Europe Revenue of AstraZeneca PLC FY 2014-FY 2018 (in USD billion)
Exhibit 8.59 Rest of Europe Revenue Growth of AstraZeneca PLC FY 2015-FY 2018 (in %)
Exhibit 8.60 Rest of Europe Revenue of AstraZeneca PLC FY 2014-FY 2018 (in USD billion)
Exhibit 8.61 Canada Revenue Growth of AstraZeneca PLC FY 2015-FY 2018 (in %)
Exhibit 8.62 Rest of Americas Revenue of AstraZeneca PLC FY 2014-FY 2018 (in USD billion)
Exhibit 8.63 Rest of Americas Revenue Growth of AstraZeneca PLC FY 2015-FY 2018 (in %)
Exhibit 8.64 Australia Revenue of AstraZeneca PLC FY 2014-FY 2018 (in USD billion)
Exhibit 8.65 Australia Revenue Growth of AstraZeneca PLC FY 2015-FY 2018 (in %)
Exhibit 8.66 Japan Revenue of AstraZeneca PLC FY 2014-FY 2018 (in USD billion)
Exhibit 8.67 Japan Revenue Growth of AstraZeneca PLC FY 2015-FY 2018 (in %)
Exhibit 8.68 Rest of Asia, Africa & Australia Revenue of AstraZeneca PLC FY 2014-FY 2018 (in USD billion)
Exhibit 8.69 Rest of Asia, Africa & Australia Revenue Growth of AstraZeneca PLC FY 2015-FY 2018 (in %)
Exhibit 8.70 Therapy Area-Wise Revenue of AstraZeneca PLC in FY 2018 (in USD billion)
Exhibit 8.71 Therapy and Geography Area-Wise Revenue of AstraZeneca PLC FY 2018 (in USD billion)
Exhibit 8.72 SWOT Analysis of AstraZeneca PLC
Exhibit 8.73 Key Information of Roche Holding AG
Exhibit 8.74 Contact Information of Roche Holding AG
Exhibit 8.75 Roche Holding AG in Global Pharmaceutical Manufacturing Value Chain
Exhibit 8.76 Revenue of Roche Holding AG FY 2013- FY 2019 (in CHF billion)
Exhibit 8.77 Revenue Growth of Roche Holding AG FY 2014- FY 2019 (in %)
Exhibit 8.78 Geography-Wise Revenue of Roche Holding AG in FY 2018 (in CHF billion)
Exhibit 8.79 Division-Wise Revenue of Roche Holding AG in FY 2018 (in CHF billion)
Exhibit 8.80 Pharmaceuticals Division Revenue of Roche Holding AG FY 2013- FY 2018 (in CHF billion)
Exhibit 8.81 County-Wise Pharmaceuticals Division Revenue of Roche Holding AG FY 2018 (in CHF billion)
Exhibit 8.82 Diagnostics Division Revenue of Roche Holding AG FY 2013- FY 2018 (in CHF billion)
Exhibit 8.83 County-Wise Diagnostics Division Revenue of Roche Holding AG FY 2018 (in CHF billion)
Exhibit 8.84 Therapy Area-Wise Revenue of Roche Holding AG in FY 2018 (in CHF billion)
Exhibit 8.85 Therapy Area-Wise Pharmaceuticals Revenue of Roche Holding AG FY 2018 (in CHF billion)
Exhibit 8.86 Segment-Wise Diagnostics Revenue of Roche Holding AG FY 2018 (in CHF billion)
Exhibit 8.87 SWOT Analysis of Roche Holding AG
Exhibit 8.88 Roche Holding AG Pharmaceuticals Product Pipeline
Exhibit 8.89 Key Information of Merck & Co.
Exhibit 8.90 Contact Information of Merck & Co.
Exhibit 8.91 Merck & Co., Inc. in Global Pharmaceuticals Manufacturing Value Chain
Exhibit 8.92 Revenue of Merck & Co., Inc. FY 2013- FY 2019 (in USD billion)
Exhibit 8.93 Revenue Growth of Merck & Co., Inc. FY 2014-FY 2019 (in %)
Exhibit 8.94 Division-Wise Revenue of Merck & Co., Inc. in FY 2018 (in USD billion)
Exhibit 8.95 Pharmaceuticals Division Revenue of Merck & Co., Inc. FY 2013- FY 2018 (in USD billion)
Exhibit 8.96 Animal Health Division Revenue of Merck & Co., Inc. FY 2013- FY 2018 (in USD billion)
Exhibit 8.97 Geography-Wise Revenue of Merck & Co., Inc. in FY 2018 (in USD billion)
Exhibit 8.98 Therapy Area-Wise Revenue of Merck & Co., Inc. in FY 2018 (in USD billion)
Exhibit 8.99 Business Division, Therapy Area and Geography Area-Wise Revenue of Merck & Co., Inc. FY 2018 (in USD billion)
Exhibit 8.100 SWOT Analysis of Merck & Co., Inc.
Exhibit 8.101 Key Information of Astellas Pharma Inc
Exhibit 8.102 Contact information of Astellas Pharma Inc
Exhibit 8.103 Astellas Pharma Inc in Pharmaceuticals Manufacturing Value Chain
Exhibit 8.104 Revenue of Astellas Pharma Inc FY 2013-FY 2019 (in USD billion)
Exhibit 8.105 Revenue Growth of Astellas Pharma Inc FY 2014-FY 2019 (in %)
Exhibit 8.106 Geography-Wise Revenue of Astellas Pharma Inc in FY 2018 (in USD billion)
Exhibit 8.107 Japan Revenue of Astellas Pharma Inc FY 2014-FY 2018 (in USD billion)
Exhibit 8.108 Japan Revenue Growth of Astellas Pharma Inc FY 2015-FY 2018 (in %)
Exhibit 8.109 Americas Revenue of Astellas Pharma Inc FY 2014-FY 2018 (in USD billion)
Exhibit 8.110 Americas Revenue Growth of Astellas Pharma Inc FY 2015-FY 2018 (in %)
Exhibit 8.111 EMEA Revenue of Astellas Pharma Inc FY 2014-FY 2018 (in USD billion)
Exhibit 8.112 EMEA Revenue Growth of Astellas Pharma Inc FY 2015-FY 2018 (in %)
Exhibit 8.113 Asia & Oceania Revenue of Astellas Pharma Inc FY 2014-FY 2018 (in USD billion)
Exhibit 8.114 Asia & Oceania Revenue Growth of Astellas Pharma Inc FY 2015-FY 2018 (in %)
Exhibit 8.115 Therapy Area-Wise Revenue of Astellas Pharma Inc in FY 2018 (in USD billion)
Exhibit 8.116 Therapy and Geography Area-Wise Revenue of Astellas Pharma Inc FY 2018 (in USD billion)
Exhibit 8.117 SWOT Analysis of Astellas Pharma Inc
Exhibit 8.118 Key information of AbbVie Inc.
Exhibit 8.119 Contact Information of AbbVie. Inc.
Exhibit 8.120 AbbVie. Inc. in Global Pharmaceuticals Manufacturing Value Chain
Exhibit 8.121 Revenue of AbbVie Inc. FY 2013- FY 2019 (in USD billion)
Exhibit 8.122 Revenue Growth of AbbVie Inc. FY 2014-FY 2019 (in %)
Exhibit 8.123 Geography-Wise Revenue of AbbVie Inc. in FY 2018 (in USD billion)
Exhibit 8.124 Therapy Area-Wise Revenue of AbbVie Inc. in FY 2018 (in USD billion)
Exhibit 8.125 Therapy Area and Geography Area-Wise Revenue of AbbVie Inc. FY 2018 (in USD billion)
Exhibit 8.126 SWOT Analysis of AbbVie Inc.
Exhibit 8.127 Key information of Eli Lilly
Exhibit 8.128 Contact Information Eli Lilly
Exhibit 8.129 Eli Lilly in Pharmaceuticals Manufacturing Value Chain
Exhibit 8.130 Revenue of Eli Lilly and Company FY 2013-FY 2019 (in USD billion)
Exhibit 8.131 Revenue Growth of Eli Lilly and Company FY 2014-FY 2019 (in %)
Exhibit 8.132 Geography-Wise Revenue of Eli Lilly and Company in FY 2018 (in USD billion)
Exhibit 8.133 United States Revenue of Eli Lilly and Company FY 2013-FY 2018 (in USD billion)
Exhibit 8.134 United States Revenue Growth of Eli Lilly and Company FY 2014-FY 2018 (in %)
Exhibit 8.135 Rest of World Revenue of Eli Lilly and Company FY 2013-FY 2018 (in USD billion)
Exhibit 8.136 Rest of World Revenue Growth of Eli Lilly and Company FY 2014-FY 2018 (in %)
Exhibit 8.137 Division-Wise Revenue of Eli Lilly and Company in FY 2018 (in USD billion)
Exhibit 8.138 Pharmaceuticals Division Revenue of Eli Lilly and Company FY 2013- FY 2018 (in USD billion)
Exhibit 8.139 Animal Health Division Revenue of Eli Lilly and Company FY 2013- FY 2018 (in USD billion)
Exhibit 8.140 Geography-Wise Pharmaceuticals Revenue of Eli Lilly and Company in FY 2018 (in USD billion)
Exhibit 8.141 United States Pharmaceuticals Revenue of Eli Lilly and Company FY 2013-FY 2018 (in USD billion)
Exhibit 8.142 Europe States Pharmaceuticals Revenue of Eli Lilly and Company FY 2013-FY 2018 (in USD billion)
Exhibit 8.143 Japan Pharmaceuticals Revenue of Eli Lilly and Company FY 2013-FY 2018 (in USD billion)
Exhibit 8.144 Rest of World Pharmaceuticals Revenue of Eli Lilly and Company FY 2013-FY 2018 (in USD billion)
Exhibit 8.145 Therapy Area-Wise Revenue of Eli Lilly and Company in FY 2018 (in USD billion)
Exhibit 8.146 Business Division-Wise, Therapy and Geography Area-Wise Revenue of Eli Lilly and Company FY 2018 (in USD million)
Exhibit 8.147 SWOT Analysis of Eli Lilly and Company
Exhibit 8.148 Key Information of Bristol-Myers Squib Company
Exhibit 8.149 Contact Information of Bristol-Myers Squib Company
Exhibit 8.150 Bristol-Myers Squib Company in Global Pharmaceuticals Manufacturing Value Chain
Exhibit 8.151 Revenue of Bristol-Myers Squibb Company FY 2013-FY 2019 (in USD billion)
Exhibit 8.152 Revenue Growth of Bristol-Myers Squibb Company FY 2014-FY 2019 (in %)
Exhibit 8.153 Geography-Wise Revenue of Bristol-Myers Squibb Company in FY 2018 (in USD billion)
Exhibit 8.154 United States Revenue of Bristol-Myers Squibb Company FY 2013-FY 2018 (in USD billion)
Exhibit 8.155 United States Revenue Growth of Bristol-Myers Squibb Company FY 2014-FY 2018 (in %)
Exhibit 8.156 Europe Revenue of Bristol-Myers Squibb Company FY 2013-FY 2018 (in USD billion)
Exhibit 8.157 Europe Revenue Growth of Bristol-Myers Squibb Company FY 2014-FY 2018 (in %)
Exhibit 8.158 Rest of World Revenue of Bristol-Myers Squibb Company FY 2013-FY 2018 (in USD billion)
Exhibit 8.159 Rest of World Revenue Growth of Bristol-Myers Squibb Company FY 2014-FY 2018 (in %)
Exhibit 8.160 Other Revenue of Bristol-Myers Squibb Company FY 2013-FY 2018 (in USD billion)
Exhibit 8.161 Other Revenue Growth of Bristol-Myers Squibb Company FY 2014-FY 2018 (in %)
Exhibit 8.162 Brand-Wise Pharmaceuticals Revenue of Bristol-Myers Squibb Company FY 2018 (in USD billion)
Exhibit 8.163 SWOT Analysis of Bristol-Myers Squib Company
Exhibit 9.1 Competitive Landscape Among Top 10 Oncology Companies by Oncology Revenue for FY2018 (in USD billion)
Exhibit 9.2 Competitive Landscape Among Top 10 Oncology Companies by Overall Revenue for FY2018 (in USD billion)
Exhibit 9.3 Competitive Landscape Among Top 10 Oncology Companies by Global Pharmaceuticals Revenue for FY2018 (in USD billion)
Exhibit 9.4 Competitive Landscape Among Top 10 Oncology Companies by United States Revenue for FY2018 (in USD billion)
Exhibit 9.5 Competitive Landscape Among Top 10 Oncology Companies by Research and Development (R&D) Expenditure for FY2018 (in USD billion)
Exhibit 9.6 Competitive Landscape Among Top 10 Oncology Companies by Research and Earning Per Share (EPS) and EBITDA for FY2018 (in USD)
Exhibit 9.7 Competitive Landscape Among Top 10 Oncology Companies by Earnings Before Interest, Tax, Depreciation and Amortization (EBITDA) for FY2018 (in USD billion)
Exhibit 9.8 Competitive Landscape Among Top 10 Oncology Companies by Overall Revenue Forecast for FY2019 (in USD billion)
Exhibit 9.9 Competitive Landscape Among Top 10 Oncology Companies by 3 Blockbuster Product Revenue for FY2018 (in USD billion)
Exhibit 10.1 Porter’s Five Forces Analysis for Global Oncology Market
Exhibit 10.2 SWOT Analysis for Global Oncology Market
Exhibit 2.1 Research and Development Phases of Pharmaceuticals Industry
Exhibit 2.2 Industry-Wise Research and Development Investment in Comparison to Net Sales (in %)
Exhibit 2.3 Phase-Wise Research and Development Investment in Pharmaceuticals Industry
Exhibit 2.4 Global Pharmaceuticals Industry Value Chain Analysis
Exhibit 3.1 Country-Wise Population Forecast 2016-2023 (in millions)
Exhibit 3.2 Country-Wise Purchasing Power Parity Based Per Capita GDP Forecast 2016-2023 (in USD)
Exhibit 4.1 Therapy Area-wise Market Share in Global Pharmaceuticals Market in 2017 (in %)
Exhibit 4.2 Forecast for Global Oncology Pharmaceuticals Market 2018-2023 (in USD billion)
Exhibit 5.1 Growth Drivers and Inhibitors for Global Oncology Market
Exhibit 6.1 Country-Wise Drug Price Control Policies in Global Pharmaceuticals Market
Exhibit 7.1 Key Information of EFPIA
Exhibit 7.2 Contact details of EFPIA
Exhibit 7.3 List of EFPIA Members
Exhibit 7.4 Key Information of IFPMA
Exhibit 7.5 Contact details of IFPMA
Exhibit 7.6 List of IFPMA Members
Exhibit 7.7 Key Information of PhRMA
Exhibit 7.8 Contact details of PhRMA
Exhibit 7.9 List of PhRMA Members
Exhibit 7.10 Key information of ABPI
Exhibit 7.11 Contact details of ABPI
Exhibit 7.12 List of ABPI Members
Exhibit 7.13 Key Information of JPMA
Exhibit 7.13 Key Information of JPMA
Exhibit 7.15 List of JPMA Members
Exhibit 7.16 Key information of IDMA
Exhibit 7.17 Contact details of IDMA
Exhibit 8.1 Key Information of Pfizer Inc.
Exhibit 8.2 Contact information of Pfizer Inc.
Exhibit 8.3 Pfizer Inc. in Pharmaceuticals Manufacturing Value Chain
Exhibit 8.4 Revenue of Pfizer Inc. FY 2013- FY 2019 (in USD billion)
Exhibit 8.5 Revenue Growth of Pfizer Inc. FY 2014- FY 2019 (in %)
Exhibit 8.6 Geography-Wise Revenue of Pfizer Inc. in FY 2018 (in USD billion)
Exhibit 8.7 Therapy Area-Wise Revenue of Pfizer Inc. in FY 2018 (in USD billion)
Exhibit 8.8 Therapy and Geography Area-Wise Revenue of Pfizer Inc. FY 2018 (in USD billion)j
Exhibit 8.9 SWOT Analysis of Pfizer Inc.
Exhibit 8.10 Key Information of Novartis AG
Exhibit 8.11 Contact Information of Novartis AG
Exhibit 8.12 Novartis AG in Pharmaceuticals Manufacturing Value Chain
Exhibit 8.13 Revenue of Novartis AG FY 2013- FY 2019 (in USD billion)
Exhibit 8.14 Revenue Growth of Novartis AG FY 2014- FY 2019 (in %)
Exhibit 8.15 Geography-Wise Revenue of Novartis AG in FY 2018 (in USD billion)
Exhibit 8.16 Therapy and Geography Area-Wise Revenue of Pfizer Inc. FY 2018 (in USD million)
Exhibit 8.17 Business Division-Wise Revenue of Novartis AG in FY 2018 (in USD million)
Exhibit 8.18 Innovative Medicines Division Revenue of Novartis AG FY 2017- FY 2019 (in USD billion)
Exhibit 8.19 Sandoz Division Revenue of Novartis AG FY 2017- FY 2019 (in USD billion)
Exhibit 8.20 Alcon Division Revenue of Novartis AG FY 2017- FY 2019 (in USD billion)
Exhibit 8.21 10+ potential blockbuster launches planned by Novartis AG in the next 2 years
Exhibit 8.22 SWOT Analysis of Novartis AG
Exhibit 8.23 Key Information of Johnson & Johnson
Exhibit 8.24 Contact information of Johnson & Johnson
Exhibit 8.25 Johnson & Johnson in Pharmaceuticals Manufacturing Value Chain
Exhibit 8.26 Revenue of Johnson & Johnson FY 2013- FY 2019 (in USD billion)
Exhibit 8.27 Revenue Growth of Johnson & Johnson FY 2014- FY 2019 (in %)
Exhibit 8.28 Division-Wise Revenue of Johnson & Johnson in FY 2018 (in USD billion)
Exhibit 8.29 Consumer Division Revenue of Johnson & Johnson FY 2013- FY 2018 (in USD billion)
Exhibit 8.30 Pharmaceuticals Division Revenue of Johnson & Johnson FY 2013- FY 2018 (in USD billion)
Exhibit 8.31 Medical Devices Division Revenue of Johnson & Johnson FY 2013- FY 2018 (in USD billion)
Exhibit 8.32 Geography-Wise Revenue of Johnson & Johnson in FY 2018 (in USD billion)
Exhibit 8.33 Therapy Area-Wise Revenue of Johnson & Johnson in FY 2018 (in USD billion)
Exhibit 8.34 Therapy and Geography Area-Wise Revenue of Johnson & Johnson FY 2018 (in USD billion)
Exhibit 8.35 SWOT Analysis of Johnson & Johnson
Exhibit 8.36 Key Information of AstraZeneca PLC
Exhibit 8.37 Contact Information of AstraZeneca PLC
Exhibit 8.38 AstraZeneca PLC in Pharmaceuticals Manufacturing Value Chain
Exhibit 8.39 Revenue of AstraZeneca PLC FY 2013-FY 2019 (in USD billion)
Exhibit 8.40 Revenue Growth of AstraZeneca PLC FY 2014-FY 2019 (in %)
Exhibit 8.41 Geography-Wise Revenue of AstraZeneca PLC in FY 2018 (in USD billion)
Exhibit 8.42 United States Revenue of AstraZeneca PLC FY 2014-FY 2018 (in USD billion)
Exhibit 8.43 United States Revenue Growth of AstraZeneca PLC FY 2015-FY 2018 (in %)
Exhibit 8.44 China Revenue of AstraZeneca PLC FY 2014-FY 2018 (in USD billion)
Exhibit 8.45 China Revenue Growth of AstraZeneca PLC FY 2015-FY 2018 (in %)
Exhibit 8.46 United Kingdom Revenue of AstraZeneca PLC FY 2014-FY 2018 (in USD billion)
Exhibit 8.47 United Kingdom Revenue Growth of AstraZeneca PLC FY 2015-FY 2018 (in %)
Exhibit 8.48 France Revenue of AstraZeneca PLC FY 2014-FY 2018 (in USD billion)
Exhibit 8.49 France Revenue Growth of AstraZeneca PLC FY 2015-FY 2018 (in %)
Exhibit 8.50 Germany Revenue of AstraZeneca PLC FY 2014-FY 2018 (in USD billion)
Exhibit 8.51 Germany Revenue Growth of AstraZeneca PLC FY 2015-FY 2018 (in %)
Exhibit 8.52 Italy Revenue of AstraZeneca PLC FY 2014-FY 2018 (in USD billion)
Exhibit 8.53 Italy Revenue Growth of AstraZeneca PLC FY 2015-FY 2018 (in %)
Exhibit 8.54 Spain Revenue of AstraZeneca PLC FY 2014-FY 2018 (in USD billion)
Exhibit 8.55 Spain Revenue Growth of AstraZeneca PLC FY 2015-FY 2018 (in %)
Exhibit 8.56 Sweden Revenue of AstraZeneca PLC FY 2014-FY 2018 (in USD billion)
Exhibit 8.57 Sweden Revenue Growth of AstraZeneca PLC FY 2015-FY 2018 (in %)
Exhibit 8.58 Rest of Europe Revenue of AstraZeneca PLC FY 2014-FY 2018 (in USD billion)
Exhibit 8.59 Rest of Europe Revenue Growth of AstraZeneca PLC FY 2015-FY 2018 (in %)
Exhibit 8.60 Rest of Europe Revenue of AstraZeneca PLC FY 2014-FY 2018 (in USD billion)
Exhibit 8.61 Canada Revenue Growth of AstraZeneca PLC FY 2015-FY 2018 (in %)
Exhibit 8.62 Rest of Americas Revenue of AstraZeneca PLC FY 2014-FY 2018 (in USD billion)
Exhibit 8.63 Rest of Americas Revenue Growth of AstraZeneca PLC FY 2015-FY 2018 (in %)
Exhibit 8.64 Australia Revenue of AstraZeneca PLC FY 2014-FY 2018 (in USD billion)
Exhibit 8.65 Australia Revenue Growth of AstraZeneca PLC FY 2015-FY 2018 (in %)
Exhibit 8.66 Japan Revenue of AstraZeneca PLC FY 2014-FY 2018 (in USD billion)
Exhibit 8.67 Japan Revenue Growth of AstraZeneca PLC FY 2015-FY 2018 (in %)
Exhibit 8.68 Rest of Asia, Africa & Australia Revenue of AstraZeneca PLC FY 2014-FY 2018 (in USD billion)
Exhibit 8.69 Rest of Asia, Africa & Australia Revenue Growth of AstraZeneca PLC FY 2015-FY 2018 (in %)
Exhibit 8.70 Therapy Area-Wise Revenue of AstraZeneca PLC in FY 2018 (in USD billion)
Exhibit 8.71 Therapy and Geography Area-Wise Revenue of AstraZeneca PLC FY 2018 (in USD billion)
Exhibit 8.72 SWOT Analysis of AstraZeneca PLC
Exhibit 8.73 Key Information of Roche Holding AG
Exhibit 8.74 Contact Information of Roche Holding AG
Exhibit 8.75 Roche Holding AG in Global Pharmaceutical Manufacturing Value Chain
Exhibit 8.76 Revenue of Roche Holding AG FY 2013- FY 2019 (in CHF billion)
Exhibit 8.77 Revenue Growth of Roche Holding AG FY 2014- FY 2019 (in %)
Exhibit 8.78 Geography-Wise Revenue of Roche Holding AG in FY 2018 (in CHF billion)
Exhibit 8.79 Division-Wise Revenue of Roche Holding AG in FY 2018 (in CHF billion)
Exhibit 8.80 Pharmaceuticals Division Revenue of Roche Holding AG FY 2013- FY 2018 (in CHF billion)
Exhibit 8.81 County-Wise Pharmaceuticals Division Revenue of Roche Holding AG FY 2018 (in CHF billion)
Exhibit 8.82 Diagnostics Division Revenue of Roche Holding AG FY 2013- FY 2018 (in CHF billion)
Exhibit 8.83 County-Wise Diagnostics Division Revenue of Roche Holding AG FY 2018 (in CHF billion)
Exhibit 8.84 Therapy Area-Wise Revenue of Roche Holding AG in FY 2018 (in CHF billion)
Exhibit 8.85 Therapy Area-Wise Pharmaceuticals Revenue of Roche Holding AG FY 2018 (in CHF billion)
Exhibit 8.86 Segment-Wise Diagnostics Revenue of Roche Holding AG FY 2018 (in CHF billion)
Exhibit 8.87 SWOT Analysis of Roche Holding AG
Exhibit 8.88 Roche Holding AG Pharmaceuticals Product Pipeline
Exhibit 8.89 Key Information of Merck & Co.
Exhibit 8.90 Contact Information of Merck & Co.
Exhibit 8.91 Merck & Co., Inc. in Global Pharmaceuticals Manufacturing Value Chain
Exhibit 8.92 Revenue of Merck & Co., Inc. FY 2013- FY 2019 (in USD billion)
Exhibit 8.93 Revenue Growth of Merck & Co., Inc. FY 2014-FY 2019 (in %)
Exhibit 8.94 Division-Wise Revenue of Merck & Co., Inc. in FY 2018 (in USD billion)
Exhibit 8.95 Pharmaceuticals Division Revenue of Merck & Co., Inc. FY 2013- FY 2018 (in USD billion)
Exhibit 8.96 Animal Health Division Revenue of Merck & Co., Inc. FY 2013- FY 2018 (in USD billion)
Exhibit 8.97 Geography-Wise Revenue of Merck & Co., Inc. in FY 2018 (in USD billion)
Exhibit 8.98 Therapy Area-Wise Revenue of Merck & Co., Inc. in FY 2018 (in USD billion)
Exhibit 8.99 Business Division, Therapy Area and Geography Area-Wise Revenue of Merck & Co., Inc. FY 2018 (in USD billion)
Exhibit 8.100 SWOT Analysis of Merck & Co., Inc.
Exhibit 8.101 Key Information of Astellas Pharma Inc
Exhibit 8.102 Contact information of Astellas Pharma Inc
Exhibit 8.103 Astellas Pharma Inc in Pharmaceuticals Manufacturing Value Chain
Exhibit 8.104 Revenue of Astellas Pharma Inc FY 2013-FY 2019 (in USD billion)
Exhibit 8.105 Revenue Growth of Astellas Pharma Inc FY 2014-FY 2019 (in %)
Exhibit 8.106 Geography-Wise Revenue of Astellas Pharma Inc in FY 2018 (in USD billion)
Exhibit 8.107 Japan Revenue of Astellas Pharma Inc FY 2014-FY 2018 (in USD billion)
Exhibit 8.108 Japan Revenue Growth of Astellas Pharma Inc FY 2015-FY 2018 (in %)
Exhibit 8.109 Americas Revenue of Astellas Pharma Inc FY 2014-FY 2018 (in USD billion)
Exhibit 8.110 Americas Revenue Growth of Astellas Pharma Inc FY 2015-FY 2018 (in %)
Exhibit 8.111 EMEA Revenue of Astellas Pharma Inc FY 2014-FY 2018 (in USD billion)
Exhibit 8.112 EMEA Revenue Growth of Astellas Pharma Inc FY 2015-FY 2018 (in %)
Exhibit 8.113 Asia & Oceania Revenue of Astellas Pharma Inc FY 2014-FY 2018 (in USD billion)
Exhibit 8.114 Asia & Oceania Revenue Growth of Astellas Pharma Inc FY 2015-FY 2018 (in %)
Exhibit 8.115 Therapy Area-Wise Revenue of Astellas Pharma Inc in FY 2018 (in USD billion)
Exhibit 8.116 Therapy and Geography Area-Wise Revenue of Astellas Pharma Inc FY 2018 (in USD billion)
Exhibit 8.117 SWOT Analysis of Astellas Pharma Inc
Exhibit 8.118 Key information of AbbVie Inc.
Exhibit 8.119 Contact Information of AbbVie. Inc.
Exhibit 8.120 AbbVie. Inc. in Global Pharmaceuticals Manufacturing Value Chain
Exhibit 8.121 Revenue of AbbVie Inc. FY 2013- FY 2019 (in USD billion)
Exhibit 8.122 Revenue Growth of AbbVie Inc. FY 2014-FY 2019 (in %)
Exhibit 8.123 Geography-Wise Revenue of AbbVie Inc. in FY 2018 (in USD billion)
Exhibit 8.124 Therapy Area-Wise Revenue of AbbVie Inc. in FY 2018 (in USD billion)
Exhibit 8.125 Therapy Area and Geography Area-Wise Revenue of AbbVie Inc. FY 2018 (in USD billion)
Exhibit 8.126 SWOT Analysis of AbbVie Inc.
Exhibit 8.127 Key information of Eli Lilly
Exhibit 8.128 Contact Information Eli Lilly
Exhibit 8.129 Eli Lilly in Pharmaceuticals Manufacturing Value Chain
Exhibit 8.130 Revenue of Eli Lilly and Company FY 2013-FY 2019 (in USD billion)
Exhibit 8.131 Revenue Growth of Eli Lilly and Company FY 2014-FY 2019 (in %)
Exhibit 8.132 Geography-Wise Revenue of Eli Lilly and Company in FY 2018 (in USD billion)
Exhibit 8.133 United States Revenue of Eli Lilly and Company FY 2013-FY 2018 (in USD billion)
Exhibit 8.134 United States Revenue Growth of Eli Lilly and Company FY 2014-FY 2018 (in %)
Exhibit 8.135 Rest of World Revenue of Eli Lilly and Company FY 2013-FY 2018 (in USD billion)
Exhibit 8.136 Rest of World Revenue Growth of Eli Lilly and Company FY 2014-FY 2018 (in %)
Exhibit 8.137 Division-Wise Revenue of Eli Lilly and Company in FY 2018 (in USD billion)
Exhibit 8.138 Pharmaceuticals Division Revenue of Eli Lilly and Company FY 2013- FY 2018 (in USD billion)
Exhibit 8.139 Animal Health Division Revenue of Eli Lilly and Company FY 2013- FY 2018 (in USD billion)
Exhibit 8.140 Geography-Wise Pharmaceuticals Revenue of Eli Lilly and Company in FY 2018 (in USD billion)
Exhibit 8.141 United States Pharmaceuticals Revenue of Eli Lilly and Company FY 2013-FY 2018 (in USD billion)
Exhibit 8.142 Europe States Pharmaceuticals Revenue of Eli Lilly and Company FY 2013-FY 2018 (in USD billion)
Exhibit 8.143 Japan Pharmaceuticals Revenue of Eli Lilly and Company FY 2013-FY 2018 (in USD billion)
Exhibit 8.144 Rest of World Pharmaceuticals Revenue of Eli Lilly and Company FY 2013-FY 2018 (in USD billion)
Exhibit 8.145 Therapy Area-Wise Revenue of Eli Lilly and Company in FY 2018 (in USD billion)
Exhibit 8.146 Business Division-Wise, Therapy and Geography Area-Wise Revenue of Eli Lilly and Company FY 2018 (in USD million)
Exhibit 8.147 SWOT Analysis of Eli Lilly and Company
Exhibit 8.148 Key Information of Bristol-Myers Squib Company
Exhibit 8.149 Contact Information of Bristol-Myers Squib Company
Exhibit 8.150 Bristol-Myers Squib Company in Global Pharmaceuticals Manufacturing Value Chain
Exhibit 8.151 Revenue of Bristol-Myers Squibb Company FY 2013-FY 2019 (in USD billion)
Exhibit 8.152 Revenue Growth of Bristol-Myers Squibb Company FY 2014-FY 2019 (in %)
Exhibit 8.153 Geography-Wise Revenue of Bristol-Myers Squibb Company in FY 2018 (in USD billion)
Exhibit 8.154 United States Revenue of Bristol-Myers Squibb Company FY 2013-FY 2018 (in USD billion)
Exhibit 8.155 United States Revenue Growth of Bristol-Myers Squibb Company FY 2014-FY 2018 (in %)
Exhibit 8.156 Europe Revenue of Bristol-Myers Squibb Company FY 2013-FY 2018 (in USD billion)
Exhibit 8.157 Europe Revenue Growth of Bristol-Myers Squibb Company FY 2014-FY 2018 (in %)
Exhibit 8.158 Rest of World Revenue of Bristol-Myers Squibb Company FY 2013-FY 2018 (in USD billion)
Exhibit 8.159 Rest of World Revenue Growth of Bristol-Myers Squibb Company FY 2014-FY 2018 (in %)
Exhibit 8.160 Other Revenue of Bristol-Myers Squibb Company FY 2013-FY 2018 (in USD billion)
Exhibit 8.161 Other Revenue Growth of Bristol-Myers Squibb Company FY 2014-FY 2018 (in %)
Exhibit 8.162 Brand-Wise Pharmaceuticals Revenue of Bristol-Myers Squibb Company FY 2018 (in USD billion)
Exhibit 8.163 SWOT Analysis of Bristol-Myers Squib Company
Exhibit 9.1 Competitive Landscape Among Top 10 Oncology Companies by Oncology Revenue for FY2018 (in USD billion)
Exhibit 9.2 Competitive Landscape Among Top 10 Oncology Companies by Overall Revenue for FY2018 (in USD billion)
Exhibit 9.3 Competitive Landscape Among Top 10 Oncology Companies by Global Pharmaceuticals Revenue for FY2018 (in USD billion)
Exhibit 9.4 Competitive Landscape Among Top 10 Oncology Companies by United States Revenue for FY2018 (in USD billion)
Exhibit 9.5 Competitive Landscape Among Top 10 Oncology Companies by Research and Development (R&D) Expenditure for FY2018 (in USD billion)
Exhibit 9.6 Competitive Landscape Among Top 10 Oncology Companies by Research and Earning Per Share (EPS) and EBITDA for FY2018 (in USD)
Exhibit 9.7 Competitive Landscape Among Top 10 Oncology Companies by Earnings Before Interest, Tax, Depreciation and Amortization (EBITDA) for FY2018 (in USD billion)
Exhibit 9.8 Competitive Landscape Among Top 10 Oncology Companies by Overall Revenue Forecast for FY2019 (in USD billion)
Exhibit 9.9 Competitive Landscape Among Top 10 Oncology Companies by 3 Blockbuster Product Revenue for FY2018 (in USD billion)
Exhibit 10.1 Porter’s Five Forces Analysis for Global Oncology Market
Exhibit 10.2 SWOT Analysis for Global Oncology Market
